Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ventricular arrhythmias and sudden death events following acalabrutinib initiation.
Bhat SA, Gambril J, Azali L, Chen ST, Rosen L, Palettas M, Wiczer TE, Kalathoor S, Zhao Q, Rogers KA, Kittai A, Grever M, Awan F, Ruz P, Byrd JC, Woyach J, Addison D. Bhat SA, et al. Among authors: woyach j. Blood. 2022 Nov 17;140(20):2142-2145. doi: 10.1182/blood.2022016953. Blood. 2022. PMID: 35917449 Free PMC article.
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.
Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT. Wiczer TE, et al. Among authors: woyach j. Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. eCollection 2017 Sep 12. Blood Adv. 2017. PMID: 29296820 Free PMC article.
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation.
Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, Gambril J, Kola-Kehinde O, Ruz P, Kalathoor S, Rogers K, Kittai A, Grever M, Awan F, Byrd JC, Woyach J, Bhat SA, Addison D. Chen ST, et al. Among authors: woyach j. J Hematol Oncol. 2022 Jul 14;15(1):92. doi: 10.1186/s13045-022-01302-7. J Hematol Oncol. 2022. PMID: 35836241 Free PMC article.
A CAPTIVATE-ing new regimen for CLL.
Rogers KA, Woyach JA. Rogers KA, et al. Blood. 2022 Jun 2;139(22):3229-3230. doi: 10.1182/blood.2022015963. Blood. 2022. PMID: 35653166 Free article. No abstract available.
Hypertension and incident cardiovascular events following ibrutinib initiation.
Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhat S, Byrd JC, Woyach JA, Awan F, Addison D. Dickerson T, et al. Among authors: woyach ja. Blood. 2019 Nov 28;134(22):1919-1928. doi: 10.1182/blood.2019000840. Blood. 2019. PMID: 31582362 Free PMC article. Clinical Trial.
Boosting BNT162b2 vaccine efficacy in CLL.
Bhat SA, Woyach JA. Bhat SA, et al. Blood. 2022 Feb 3;139(5):639-640. doi: 10.1182/blood.2021014903. Blood. 2022. PMID: 35113151 Free PMC article. No abstract available.
uMRD: "the" endpoint or "an" endpoint for CLL?
Kittai AS, Woyach JA. Kittai AS, et al. Blood. 2022 Aug 25;140(8):797-798. doi: 10.1182/blood.2022016927. Blood. 2022. PMID: 36006672 Free article. No abstract available.
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE 3rd, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC. McWilliams EM, et al. Among authors: woyach j. Blood Adv. 2019 Feb 12;3(3):447-460. doi: 10.1182/bloodadvances.2018025684. Blood Adv. 2019. PMID: 30737226 Free PMC article.
191 results